» Articles » PMID: 29692414

A-to-I RNA Editing - Immune Protector and Transcriptome Diversifier

Overview
Journal Nat Rev Genet
Specialty Genetics
Date 2018 Apr 26
PMID 29692414
Citations 276
Authors
Affiliations
Soon will be listed here.
Abstract

Modifications of RNA affect its function and stability. RNA editing is unique among these modifications because it not only alters the cellular fate of RNA molecules but also alters their sequence relative to the genome. The most common type of RNA editing is A-to-I editing by double-stranded RNA-specific adenosine deaminase (ADAR) enzymes. Recent transcriptomic studies have identified a number of 'recoding' sites at which A-to-I editing results in non-synonymous substitutions in protein-coding sequences. Many of these recoding sites are conserved within (but not usually across) lineages, are under positive selection and have functional and evolutionary importance. However, systematic mapping of the editome across the animal kingdom has revealed that most A-to-I editing sites are located within mobile elements in non-coding parts of the genome. Editing of these non-coding sites is thought to have a critical role in protecting against activation of innate immunity by self-transcripts. Both recoding and non-coding events have implications for genome evolution and, when deregulated, may lead to disease. Finally, ADARs are now being adapted for RNA engineering purposes.

Citing Articles

Conformational reorganization and phase separation drive hyper-editing of ADR-2-ADBP-1 complex.

Mu J, Wu C, Xu K, Liu X, Fu Y, Zhang Z Nucleic Acids Res. 2025; 53(5).

PMID: 40037706 PMC: 11879458. DOI: 10.1093/nar/gkaf148.


Epitranscriptomics in the Glioma Context: A Brief Overview.

Santamarina-Ojeda P, Fernandez A, Fraga M Cancers (Basel). 2025; 17(4).

PMID: 40002173 PMC: 11853273. DOI: 10.3390/cancers17040578.


An Ultimate Question for Functional A-to-I mRNA Editing: Why Not a Genomic G?.

Xie Q, Duan Y J Mol Evol. 2025; .

PMID: 39964487 DOI: 10.1007/s00239-025-10238-8.


Taking control with RNA.

Marx V Nat Methods. 2025; 22(2):226-230.

PMID: 39905158 DOI: 10.1038/s41592-025-02596-4.


A Wonderful Journey: The Diverse Roles of Adenosine Deaminase Action on RNA 1 (ADAR1) in Central Nervous System Diseases.

Cheng L, Liu Z, Shen C, Xiong Y, Shin S, Hwang Y CNS Neurosci Ther. 2025; 31(1):e70208.

PMID: 39753993 PMC: 11702419. DOI: 10.1111/cns.70208.


References
1.
Blencowe B . Alternative splicing: new insights from global analyses. Cell. 2006; 126(1):37-47. DOI: 10.1016/j.cell.2006.06.023. View

2.
Di Giammartino D, Nishida K, Manley J . Mechanisms and consequences of alternative polyadenylation. Mol Cell. 2011; 43(6):853-66. PMC: 3194005. DOI: 10.1016/j.molcel.2011.08.017. View

3.
Boccaletto P, Machnicka M, Purta E, Piatkowski P, Baginski B, Wirecki T . MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res. 2017; 46(D1):D303-D307. PMC: 5753262. DOI: 10.1093/nar/gkx1030. View

4.
Peer E, Rechavi G, Dominissini D . Epitranscriptomics: regulation of mRNA metabolism through modifications. Curr Opin Chem Biol. 2017; 41:93-98. DOI: 10.1016/j.cbpa.2017.10.008. View

5.
Safra M, Sas-Chen A, Nir R, Winkler R, Nachshon A, Bar-Yaacov D . The m1A landscape on cytosolic and mitochondrial mRNA at single-base resolution. Nature. 2017; 551(7679):251-255. DOI: 10.1038/nature24456. View